Lexaria Bioscience Corp. (LEXX) vs Sonoma Pharmaceuticals, Inc. (SNOA)

A side-by-side comparison of Lexaria Bioscience Corp. and Sonoma Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — LEXX vs SNOA

growth of $100 · dividends reinvested · last 6y
LEXX -95.9% (-41.2%/yr)SNOA -99.3% (-55.8%/yr)LEXX compounded faster over this window
Log scale — wide-divergence pair
01101001kStart $10020222023202420252026$4$1
LEXX SNOA

LEXX vs SNOA: by the numbers

  • •SNOA is the larger company ($6M vs $5M market cap).
  • •Both run net losses; SNOA's is the smaller (-10.33% vs -3985.58% net margin).
  • •LEXX grew revenue faster over the past five years (12.92% vs 5.79% CAGR).

Metrics side by side

Valuation

MetricLEXXSNOA
P/S ratio27.600.27
P/B ratio1.130.89

Profitability

MetricLEXXSNOA
Gross margin100.00%38.91%
Operating margin-1683.01%-6.41%
Net margin-3985.58%-10.33%
ROE-163.18%-34.33%
ROIC-175.26%-10.98%

Growth (annualized)

MetricLEXXSNOA
Revenue CAGR (5Y)12.92%5.79%
Total return CAGR (5Y)-50.86%-59.29%

Frequently asked

Which has grown faster, LEXX or SNOA?
Over the past five years, LEXX grew revenue faster — LEXX at a 12.92% CAGR versus SNOA at 5.79%.
How have LEXX and SNOA total returns compared?
Over the past 5 years, LEXX delivered -50.86% and SNOA delivered -59.29% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.